{"filings":[{"id":106606,"accession_number":"0001493152-26-007574","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.","Total principal amount of $72,222.21 (~$61,500 net proceeds) at 8% interest per annum.","Notes convertible into common stock at a 35% discount to the lowest traded price over prior 20 trading days.","No warrants issued; issuance exempt under Section 4(a)(2) as sales to sophisticated investors.","Notes have a one-year maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139635,"accession_number":"0001641172-25-024303","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Three directors resign after D&O insurance lapse; $550K convertible note issued","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.","D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.","Entered agreement with Lambda Venture Partners for up to $550K principal, $500K funding; first tranche $110K/$100K.","Notes bear 8% interest, one-year term, convertible at 35% discount to lowest traded price in prior 10 days.","No warrants issued; securities sold under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175570,"accession_number":"0001493152-25-009462","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.","CEO James Joyce will serve as interim CFO following DeCiccio's retirement.","Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.","CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.","Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175569,"accession_number":"0001493152-25-002575","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sigyn Therapeutics appoints Michael Ryan to board effective Jan 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Ryan appointed to board; will serve until next stockholder meeting or successor elected.","Ryan is a founder director of Irrus Investments, largest angel syndicate in Ireland, with €40M+ invested in 35 life science and tech firms.","Compensation: $30,000 annual cash retainer plus $50,000 in restricted stock units or options, vesting quarterly over one year.","Previously CEO of Sedana Medical (Nasdaq First North) and Artema Medical (acquired by Datascope)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175568,"accession_number":"0001493152-25-001074","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sigyn Therapeutics reduces authorized common shares to 100M via charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment decreasing authorized common stock to 100 million shares (par value $0.0001).","Authorized preferred stock unchanged at 10 million shares (par value $0.0001).","Amendment effective upon filing on December 30, 2024.","No other changes to the Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192518,"accession_number":"0001493152-24-041287","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn Therapeutics exchanges 246,259 warrants for 184,699 restricted shares; no warrants outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 246,259 stock purchase warrants from 15 holders for 184,699 restricted common shares.","No warrants remain outstanding; all previously issued warrants extinguished.","Outstanding common shares increased to 1,605,377 from 1,420,678.","Transaction exempt under Section 4(a)(2); no brokerage fees paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192516,"accession_number":"0001493152-24-041285","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K/A","filed_at":"2024-10-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected prior error: sellers were not controlled by an executive officer.","$474,793 of convertible debentures converted at $4.00/share for 118,700 shares.","Shares issued with Rule 144 legend, exempt under Section 4(a)(2).","Outstanding common shares increased from 1,301,978 to 1,420,678."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192517,"accession_number":"0001493152-24-039594","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Sigyn Therapeutics issues 118,700 shares on conversion of $474,793 in debentures at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of $474,793 in convertible debentures converted at $4.00/share; 118,700 restricted shares issued.","Outstanding common shares increased from 1,301,978 to 1,420,678 as a result.","Conversion exempt from registration under Section 4(a)(2); holders are executive-officer-controlled accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226818,"accession_number":"0001493152-24-022945","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sigyn Therapeutics reports conversion of $226,903 in debentures at $6.00 per share, issuing 37,820 shares.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders converted $226,903 of Original Issue Discount Senior Convertible Debentures at avg. exercise price of $6.00/share.","Company issued 37,820 shares of common stock to debenture holders.","Outstanding common shares increased from 1,225,833 to 1,263,653 as a result.","Conversions occurred from May 30 to June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226817,"accession_number":"0001493152-24-020007","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics files PCT patent for ImmunePrep platform to enhance antibody delivery for cancer treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed PCT application US24/28579 on May 9, 2024 for 'DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES'.","Patent covers ImmunePrep platform aimed at improving delivery of immunotherapeutic antibodies for cancer.","Inventors listed: Chairman and CEO James A. Joyce and Annette M. Marleau."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226816,"accession_number":"0001493152-24-014866","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.","Osher Capital converts $621,000 debentures into 823.86 shares of Series B Convertible Preferred Stock.","Each Series B share is convertible into 125.63 common shares, subject to anti-dilution adjustments.","Brio and Osher amend additional debentures: maturity extended to March 31, 2025; principal increased to $125k and $316,350 respectively.","Additional automatic conversion of $1,856,566 aggregate debentures into Series B Preferred upon NASDAQ listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245777,"accession_number":"0001493152-24-004502","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sigyn Therapeutics effects 1-for-40 reverse stock split; symbol gets 'D' suffix for 20 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective January 30, 2024 at a 1-for-40 ratio.","Ticker symbol changes to 'SIGYD' for 20 business days per FINRA rules.","Standard symbol 'SIGY' will resume after the 20-business-day period.","No change in the company's CUSIP or par value was disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245776,"accession_number":"0001493152-24-004320","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Sigyn Therapeutics effects 1-for-40 reverse stock split effective Jan 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1-for-40 effective 12:01 a.m. ET on January 31, 2024.","Post-split shares outstanding ~1,221,043; pre-split shares were ~48.8 million.","No fractional shares; holders rounding up to next whole share automatically.","All outstanding equity awards and warrants proportionately adjusted for the split ratio.","New CUSIP number is 82674U 205; trading symbol remains SIGY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245775,"accession_number":"0001493152-24-002048","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics enters share surrender agreement with CTO to cancel 2.56M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Craig Roberts, CTO and board member, surrenders 2,564,000 shares of common stock for cancellation.","Shares are cancelled and not held as treasury shares; no further claims against the company.","As of Jan 9, 2024, total outstanding shares are 48,972,602 following this surrender and note conversions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245774,"accession_number":"0001493152-24-001690","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics shareholder letter details expanded pipeline, S-1 financing, first-in-human study plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company reveals four therapeutic platforms: Sigyn Therapy, ImmunePrep, ChemoPrep, and ChemoPure, with pending patent for chemotherapy delivery system.","S-1 registration statement filed with SEC to support underwritten financing; proceeds to advance programs and potentially qualify for Nasdaq listing.","First-in-human study of Sigyn Therapy targets ESRD patients with endotoxemia; 12-15 patient IDE drafted for FDA submission.","Clinical sites and principal investigators in place for Sigyn Therapy; treatment to be combined with dialysis.","Pipeline expansion includes devices to enhance performance of immunotherapeutic antibodies and chemotherapy delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263248,"accession_number":"0001493152-23-044529","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sigyn Therapeutics removes CFO Jeremy Ferrell, appoints Jerry DeCiccio as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Ferrell removed as CFO effective immediately; no disagreements cited.","Jerry DeCiccio appointed CFO effective immediately; he is a CPA with 40+ years experience.","DeCiccio most recently served as a consultant; holds BA from Loma Linda and MBA from USC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263247,"accession_number":"0001493152-23-038372","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sigyn Therapeutics reports conversion of $1.32M debentures into 7.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders converted $1,322,200 of Original Issue Discount Senior Convertible Debentures at $0.18/share.","Company issued 7,300,342 shares of common stock between Oct 20-25, 2023.","Outstanding shares increased from 44,231,402 to 51,531,744, a dilution of ~16.5%.","No cash proceeds were received; debt was extinguished upon conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263246,"accession_number":"0001493152-23-035700","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics discloses PCT patent filing for chemo delivery enhancement system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PCT application entitled 'SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY' submitted.","Technologies ChemoPrep and ChemoPure aim to increase tumor-site drug delivery and reduce off-target toxicity.","PCT allows simultaneous patent protection in over 150 countries; related US provisional previously filed.","Company plans first-in-human studies for Sigyn Therapy; candidate indications include sepsis and pneumonia.","Reduced chemo dosing may alleviate nationwide drug shortages, per the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280429,"accession_number":"0001493152-23-033059","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics amends convertible notes: extends maturity to Aug 2024, increases principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered amendment agreements for $2,161,316 of convertible notes, extending maturity to August 30, 2024.","Principal increased to reflect implied 12% interest rate from amendment date through new maturity.","Upon national exchange listing, notes automatically convert into Series A Convertible Preferred Stock.","Company expects to enter similar amendments with remaining holders of $3,051,516 principal notes (as of June 30, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280428,"accession_number":"0001493152-23-023932","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Sigyn Therapeutics exchanges warrants for common stock and Series A Preferred at $0.199/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Warrant Exchange Agreements with holders of warrants issued Oct 2020–Feb 2023.","Exchange ratio: 1 share of common stock for 2 warrants; certain holders receive Series A Preferred to cap beneficial ownership.","Series A Preferred converts to common at $0.199 per share, has same dividend/liquidation rights as common, no voting rights.","Preferred Stock issued to accredited investors in private placement exempt from registration under Section 4(a)(2).","Certificate of Designation for Series A Preferred filed with Delaware; no redemption rights, anti-dilution adjustments apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298985,"accession_number":"0001493152-23-020539","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sigyn Therapeutics reports conversion of convertible debentures into 1,243,000 common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 2, 2023, $16,500 debenture converted into 33,000 shares at $0.50 per share.","Also on June 2, 2023, $181,500 of other debentures converted into 1,210,000 shares at $0.15 per share.","Outstanding shares increased from 42,981,659 to 44,224,659 as a result of these conversions.","Remaining convertible debentures total $970,200 aggregate principal due through March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298984,"accession_number":"0001493152-23-012125","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics appoints Annette Marleau, Ph.D. as Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately.","Previously CTO at Immunicom and Director of Research at Aethlon Medical, advancing blood purification for cancer.","Awarded over $6 million in NIH grants; co-authored two FDA-cleared IDEs and a Breakthrough Device submission.","Inventor on patents for blood purification therapies targeting cancer, inflammatory disorders, and infectious diseases.","Her expertise supports Sigyn's pipeline including Sigyn Therapy, ChemoPrep, and ChemoPure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337388,"accession_number":"0001493152-22-027728","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2022-10-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective October 10, 2022; each director brings distinct expertise.","Jim Dorst: 30+ years finance/operations; former Director of Corporate Development at SYNNEX/Concentrix and CFO of Aethlon Medical.","Richa Nand: IP attorney and founder of Insight Patents; biomedical researcher background at Cedars Sinai.","Christopher Wetzel: CEO of Surgery Center at Hamilton since 2004; long-term investor in extracorporeal therapy.","Board cited each director's experience in financial expertise, IP, or healthcare delivery as qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391584,"accession_number":"0001493152-22-006402","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Sigyn Therapeutics appoints Jeremy Ferrell as CFO, effective March 9, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Ferrell (CPA, MBA) appointed CFO; base salary $250,000/year, annual bonus up to 40%.","Stock options for up to 600,000 shares at grant date market price; 25% vest at grant, rest over 3 years.","Employment agreement is indefinite duration, at-will; includes standard terms.","Ferrell has 25+ years finance experience; most recently CFO at Miku, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391583,"accession_number":"0001493152-22-005743","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.","One treatment halted due to clot from procedural deviation; no serious outcome observed.","Company plans to submit IDE to FDA to support initiation of human clinical studies.","In vitro studies validated broad-spectrum removal of endotoxins, cytokines, and viral pathogens.","CEO states milestone advances clinical vision for sepsis treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409795,"accession_number":"0001493152-21-026300","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K/A","filed_at":"2021-10-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sigyn Therapeutics corrects typo in prior 8-K; confirms 320K share and warrant sale for $400K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment corrects share count to 320,000 shares of common stock and warrants for 320,000 shares.","Gross proceeds from sale to accredited investors total $400,000, consummated October 20, 2021.","Warrants allow purchase of 320,000 shares of common stock; terms not specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409796,"accession_number":"0001493152-21-026239","cik":1642159,"company_name":"Sigyn Therapeutics, Inc.","ticker":"SIGY","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Sigyn Therapeutics raises $400,000 in unregistered offering of common stock and warrants at $1.25/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 320,000 shares and warrants to purchase 320,000 shares for $400,000 gross proceeds.","Each unit consists of one share and one warrant; warrant exercise price $1.25, 5-year term.","Offering exempt from registration under Section 4(a)(2) of Securities Act with accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":61004.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}